Esperion Therapeutics (ESPR) reported quarterly earnings of $0.22 per share on December 2025, missing the Zacks Consensus Estimate of $0.23 per share, but an improvement from a loss of $0.10 per share a year earlier. The company’s revenues for the quarter were $168.45 million, exceeding expectations by 4.90% and significantly up from $69.11 million in the same period last year.
Esperion has surpassed consensus revenue estimates in four out of its last four quarters, but has only met EPS estimates once in the last year. Shares of Esperion have declined approximately 17.8% year-to-date, in contrast to a 0.7% decline in the S&P 500.
Looking ahead, the consensus EPS estimate for the next quarter stands at -$0.04 on revenues of $85.48 million, while the estimate for the current fiscal year is projected at $0.18 on revenues of $404.88 million.
